M2e, human

M2e, human, also known as the extracellular domain of the matrix protein 2 from the human influenza A virus, represents a highly conserved peptide sequence that has attracted significant attention in both basic and applied research. As a small, linear peptide, M2e is characterized by its remarkable sequence conservation among various influenza A strains, making it an attractive target for multiple scientific studies. Its unique structural features enable it to be readily synthesized and manipulated in laboratory settings, facilitating a wide range of experimental applications. Researchers value M2e for its immunogenic potential, as well as its utility in the development of diagnostic reagents and vaccine research tools. The peptide's versatility is further enhanced by its compatibility with various conjugation strategies, allowing for its integration into larger protein complexes or nanoparticle platforms. Due to these attributes, M2e, human serves as a cornerstone in influenza-related research, supporting efforts to better understand viral mechanisms and host immune responses.

Vaccine Research and Development: M2e, human plays a pivotal role in the field of universal influenza vaccine development. Its highly conserved nature across diverse influenza A subtypes makes it an ideal candidate for designing broad-spectrum immunogens. Researchers frequently utilize M2e as a core antigen in experimental vaccine formulations, often conjugating it to carrier proteins or displaying it on virus-like particles to enhance immunogenicity. By eliciting M2e-specific immune responses, these vaccine candidates aim to provide cross-protective immunity against multiple influenza strains, addressing the challenge of antigenic drift and shift that undermines traditional vaccine efficacy. The use of this peptide in preclinical models has yielded valuable insights into immune mechanisms and the potential for long-lasting protection, informing next-generation vaccine strategies.

Antibody Generation and Characterization: The M2e peptide serves as a robust tool for generating and characterizing monoclonal and polyclonal antibodies specific to the influenza A M2e epitope. Scientists employ synthetic M2e, human in immunization protocols to raise antibodies that can recognize the conserved extracellular domain, facilitating studies on antibody-mediated viral neutralization and immune effector functions. These antibodies are instrumental in mapping epitope specificity, assessing the breadth of cross-reactivity among influenza strains, and evaluating the potential for passive immunization approaches. Additionally, M2e-derived antibodies provide essential reagents for downstream applications, such as immunoassays and western blotting, enabling sensitive detection of influenza A virus in diverse sample types.

Diagnostic Development: The conserved sequence of M2e, human underpins its importance in the development of influenza diagnostic assays. By incorporating the peptide as a capture antigen in ELISA or lateral flow platforms, researchers can design sensitive and specific assays for the detection of anti-M2e antibodies in serum samples. Such diagnostics offer valuable tools for serosurveillance studies, epidemiological monitoring, and the assessment of population immunity following vaccination or natural infection. The use of M2e in diagnostic settings helps overcome challenges posed by the antigenic variability of other influenza proteins, ensuring reliable detection across multiple virus subtypes and lineages.

Epitope Mapping and Structural Studies: M2e, human is widely used in epitope mapping experiments to delineate antibody binding sites and characterize the structural determinants of antigen-antibody interactions. By synthesizing variants of the M2e sequence or introducing specific amino acid substitutions, researchers can systematically probe the impact of sequence variation on antibody recognition. These studies yield critical information about the molecular basis of immune recognition and inform the rational design of epitope-based vaccines and therapeutics. Furthermore, the peptide's amenability to structural analysis techniques, such as NMR or crystallography when complexed with antibodies, provides detailed insights into conformational epitopes and immune escape mechanisms.

Adjuvant and Carrier Conjugation Studies: In addition to its direct immunogenic applications, M2e, human is frequently employed in research focused on optimizing antigen delivery and presentation. By conjugating the peptide to various adjuvants, nanoparticles, or carrier proteins, scientists can evaluate the impact of different delivery platforms on immune activation and response durability. Such studies are essential for advancing the design of next-generation vaccine candidates and understanding the interplay between antigen structure, delivery method, and host immunity. The ability to manipulate and customize M2e conjugates supports innovation in both prophylactic and therapeutic research, making it a valuable asset in the field of immunology and virology.

1. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

2. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

3. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle

4. TMEM16F and dynamins control expansive plasma membrane reservoirs

5. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes